Cargando…
Risk factors associated with fatal thrombosis in hospitalized coronavirus disease 2019 (COVID-19) patients on anticoagulant therapy
BACKGROUND: The purpose of this study was to determine the factors that increase the risk of fatal thrombotic events in hospitalized coronavirus disease 2019 (COVID-19) patients receiving standard therapy according to the National Clinical Practice Guidelines (National Guidelines). MATERIALS AND MET...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688589/ https://www.ncbi.nlm.nih.gov/pubmed/38044972 http://dx.doi.org/10.4103/jfcm.jfcm_60_23 |
_version_ | 1785152196373905408 |
---|---|
author | Kaliyeva, Sholpan Yukhnevich, Yekaterina Myasnikova, Zhanna Simokhina, Natalya Dyussembaeva, Nailya Bikbatyrova, Yuliya Drobchenko, Yelena Sagadatova, Torgin Semenikhina, Polina |
author_facet | Kaliyeva, Sholpan Yukhnevich, Yekaterina Myasnikova, Zhanna Simokhina, Natalya Dyussembaeva, Nailya Bikbatyrova, Yuliya Drobchenko, Yelena Sagadatova, Torgin Semenikhina, Polina |
author_sort | Kaliyeva, Sholpan |
collection | PubMed |
description | BACKGROUND: The purpose of this study was to determine the factors that increase the risk of fatal thrombotic events in hospitalized coronavirus disease 2019 (COVID-19) patients receiving standard therapy according to the National Clinical Practice Guidelines (National Guidelines). MATERIALS AND METHODS: In this case–control study, cases included 83 adults with COVID-19 who had died from thrombosis and controls comprised 83 COVID-19 patients with comparable criteria who survived. Data was abstracted by reviewing the medical records of selected patients and analyzed using Statistica. Parametric and non-parametric tests, as appropriate, were used to compare continuos variables between cases and controls, whereas Chi-square test was employed to compare categorical variables. Odds ratio (OR) was also calculated to measure the strength of association of case status and various independent variables. RESULTS: Fatal outcomes were higher in patients with chronic tubulointerstitial nephritis, (OR = 2.4, 95% CI 1.2–4.9); obesity, (OR = 2.1, 95% CI 0.5–8.6); and coronary heart disease (OR = 1.6, 95% CI 0.8–3.2). In the group with a D-dimer level from 250 to 1000 ng/ml, a statistically significant moderate positive correlation was found between the day of death and D-dimer level (P = 0.026). The lack of use of the PADUA Prediction Score for the risk of venous thromboembolism scale (PADUA Scale) and control of laboratory parameters (APTT and D-dimer) were associated with increased risk of fatal outcome. Overall, 19.2% cases and 8.4% of controls had no coagulation control; (OR = 2.6, 95% CI 1–6.7). CONCLUSION: Chronic tubulointerstitial nephritis, obesity, and coronary heart disease were associatied with fatal thrombosis. A slight elevation of D-dimer level, lack of the PADUA Scale and laboratory monitoring in the management of hospitalized patients with COVID-19. was associated with an increased risk of thromboembolism. |
format | Online Article Text |
id | pubmed-10688589 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-106885892023-12-01 Risk factors associated with fatal thrombosis in hospitalized coronavirus disease 2019 (COVID-19) patients on anticoagulant therapy Kaliyeva, Sholpan Yukhnevich, Yekaterina Myasnikova, Zhanna Simokhina, Natalya Dyussembaeva, Nailya Bikbatyrova, Yuliya Drobchenko, Yelena Sagadatova, Torgin Semenikhina, Polina J Family Community Med Original Article BACKGROUND: The purpose of this study was to determine the factors that increase the risk of fatal thrombotic events in hospitalized coronavirus disease 2019 (COVID-19) patients receiving standard therapy according to the National Clinical Practice Guidelines (National Guidelines). MATERIALS AND METHODS: In this case–control study, cases included 83 adults with COVID-19 who had died from thrombosis and controls comprised 83 COVID-19 patients with comparable criteria who survived. Data was abstracted by reviewing the medical records of selected patients and analyzed using Statistica. Parametric and non-parametric tests, as appropriate, were used to compare continuos variables between cases and controls, whereas Chi-square test was employed to compare categorical variables. Odds ratio (OR) was also calculated to measure the strength of association of case status and various independent variables. RESULTS: Fatal outcomes were higher in patients with chronic tubulointerstitial nephritis, (OR = 2.4, 95% CI 1.2–4.9); obesity, (OR = 2.1, 95% CI 0.5–8.6); and coronary heart disease (OR = 1.6, 95% CI 0.8–3.2). In the group with a D-dimer level from 250 to 1000 ng/ml, a statistically significant moderate positive correlation was found between the day of death and D-dimer level (P = 0.026). The lack of use of the PADUA Prediction Score for the risk of venous thromboembolism scale (PADUA Scale) and control of laboratory parameters (APTT and D-dimer) were associated with increased risk of fatal outcome. Overall, 19.2% cases and 8.4% of controls had no coagulation control; (OR = 2.6, 95% CI 1–6.7). CONCLUSION: Chronic tubulointerstitial nephritis, obesity, and coronary heart disease were associatied with fatal thrombosis. A slight elevation of D-dimer level, lack of the PADUA Scale and laboratory monitoring in the management of hospitalized patients with COVID-19. was associated with an increased risk of thromboembolism. Wolters Kluwer - Medknow 2023 2023-10-13 /pmc/articles/PMC10688589/ /pubmed/38044972 http://dx.doi.org/10.4103/jfcm.jfcm_60_23 Text en Copyright: © 2023 Journal of Family and Community Medicine https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Kaliyeva, Sholpan Yukhnevich, Yekaterina Myasnikova, Zhanna Simokhina, Natalya Dyussembaeva, Nailya Bikbatyrova, Yuliya Drobchenko, Yelena Sagadatova, Torgin Semenikhina, Polina Risk factors associated with fatal thrombosis in hospitalized coronavirus disease 2019 (COVID-19) patients on anticoagulant therapy |
title | Risk factors associated with fatal thrombosis in hospitalized coronavirus disease 2019 (COVID-19) patients on anticoagulant therapy |
title_full | Risk factors associated with fatal thrombosis in hospitalized coronavirus disease 2019 (COVID-19) patients on anticoagulant therapy |
title_fullStr | Risk factors associated with fatal thrombosis in hospitalized coronavirus disease 2019 (COVID-19) patients on anticoagulant therapy |
title_full_unstemmed | Risk factors associated with fatal thrombosis in hospitalized coronavirus disease 2019 (COVID-19) patients on anticoagulant therapy |
title_short | Risk factors associated with fatal thrombosis in hospitalized coronavirus disease 2019 (COVID-19) patients on anticoagulant therapy |
title_sort | risk factors associated with fatal thrombosis in hospitalized coronavirus disease 2019 (covid-19) patients on anticoagulant therapy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688589/ https://www.ncbi.nlm.nih.gov/pubmed/38044972 http://dx.doi.org/10.4103/jfcm.jfcm_60_23 |
work_keys_str_mv | AT kaliyevasholpan riskfactorsassociatedwithfatalthrombosisinhospitalizedcoronavirusdisease2019covid19patientsonanticoagulanttherapy AT yukhnevichyekaterina riskfactorsassociatedwithfatalthrombosisinhospitalizedcoronavirusdisease2019covid19patientsonanticoagulanttherapy AT myasnikovazhanna riskfactorsassociatedwithfatalthrombosisinhospitalizedcoronavirusdisease2019covid19patientsonanticoagulanttherapy AT simokhinanatalya riskfactorsassociatedwithfatalthrombosisinhospitalizedcoronavirusdisease2019covid19patientsonanticoagulanttherapy AT dyussembaevanailya riskfactorsassociatedwithfatalthrombosisinhospitalizedcoronavirusdisease2019covid19patientsonanticoagulanttherapy AT bikbatyrovayuliya riskfactorsassociatedwithfatalthrombosisinhospitalizedcoronavirusdisease2019covid19patientsonanticoagulanttherapy AT drobchenkoyelena riskfactorsassociatedwithfatalthrombosisinhospitalizedcoronavirusdisease2019covid19patientsonanticoagulanttherapy AT sagadatovatorgin riskfactorsassociatedwithfatalthrombosisinhospitalizedcoronavirusdisease2019covid19patientsonanticoagulanttherapy AT semenikhinapolina riskfactorsassociatedwithfatalthrombosisinhospitalizedcoronavirusdisease2019covid19patientsonanticoagulanttherapy |